Akèy › Lukemi miyomonositè kwonik › Kalifòni
Etid klinik pou Lukemi miyomonositè kwonik nan Kalifòni
12 etid pou Lukemi miyomonositè kwonik ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
Tèks ofisyèl etid la (Anglè)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Aug 17, 2026 · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- Kaiser Permanente San Diego, San Diego
- Allergy & Asthma Clinical Research of the Bay Area, Walnut Creek
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07143669Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- City of Hope Medical Center, Duarte
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Jun 29, 2026 · NCT06815003A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Keck School of Medicine of USC, Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- City of Hope, Duarte
- Stanford Medical Center, Palo Alto
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Mar 16, 2026 · NCT06994676Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT06543381A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Stanford University, Stanford
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 9, 2026 · NCT06950034Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- University of California Davis Health (UC Davis Health), Sacramento
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 5, 2026 · NCT05184842Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- University of California Irvine, Irvine
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Center, Palo Alto
- ak 1 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2025 · NCT03850574Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- City of Hope, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.